| 31.49 0 (0%) | 07-15 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.79 | 1-year : | 42.97 |
| Resists | First : | 31.5 | Second : | 36.79 |
| Pivot price | 31.47  |
|||
| Supports | First : | 31.4 | Second : | 31.34 |
| MAs | MA(5) : | 31.48 | MA(20) : | 31.46 |
| MA(100) : | 28.41 |
MA(250) : | 24.58 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 81.4 |
D(3) : | 83.4 |
| RSI | RSI(14): 70.1 | |||
| 52-week | High : | 32.56 | Low : | 19.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CPRX ] has closed below upper band by 32.7%. Bollinger Bands are 96.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 31.56 - 31.72 | 31.72 - 31.84 |
| Low: | 31.05 - 31.27 | 31.27 - 31.44 |
| Close: | 31.19 - 31.51 | 31.51 - 31.78 |
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Thu, 16 Jul 2026
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals - GlobeNewswire
Thu, 16 Jul 2026
Angelini Pharma Acquires Catalyst for $4.1B - AllSci
Thu, 16 Jul 2026
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - reuters.com
Wed, 15 Jul 2026
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock - Stock Titan
Fri, 10 Jul 2026
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Wed, 24 Jun 2026
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 122 (M) |
| Shares Float | 116 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 7,850 (K) |
| Shares Short P.Month | 8,190 (K) |
| EPS | 1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.28 |
| Profit Margin | 37 % |
| Operating Margin | 49 % |
| Return on Assets (ttm) | 16.2 % |
| Return on Equity (ttm) | 24.5 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 4.09 |
| Sales Per Share | 4.87 |
| EBITDA (p.s.) | 2.49 |
| Qtrly Earnings Growth | 11.1 % |
| Operating Cash Flow | 208 (M) |
| Levered Free Cash Flow | 172 (M) |
| PE Ratio | 18.2 |
| PEG Ratio | 0 |
| Price to Book value | 3.79 |
| Price to Sales | 6.45 |
| Price to Cash Flow | 18.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|